The NLRP3 inflammasome - interleukin 1 pathway as a therapeutic target in gout

Z. Szekanecz, Szilvia Szamosi, Gergő E. Kovács, Elek Kocsis, Sz. Benkő

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

The NLRP3 inflammasome is implicated in the processing of the pro-inflammatory cytokine interleukin 1β. Inflammatory disorders associated with the activation of the NLRP3 inflammasome - IL-1 axis are termed autoinflammatory diseases. Gout is an autoinflammatory disease, which is triggered by the deposition of monosodium urate crystals of precipitated uric acid. It is characterized by recurrent attacks of inflammation due to the activation of phagocytic cells that try to clear the crystals. NLRP3 inflammasome-mediated IL-1β production plays a key role in the manifestation of the disease. Currently, the best approach to treat gout is to reduce uric acid concentration by targeting xanthine oxidase or uric acid transporters, or to use non-steroidal anti-inflammatory drugs. Nevertheless, most of these treatments are not effective enough and may results in side effects. During the past decades, our knowledge has greatly improved about the molecular mechanisms of NLRP3 activation. This knowledge enables and urges scientists to discover or design drugs that target pathways of NLRP3 inflammasome activation, or more preferentially, NLRP3 inflammasome itself. In this review, we discuss the already available drugs and products, that target the diverse pathways of the NLRP3 - IL-1β axis, and the future therapeutic perspectives.

Original languageEnglish
JournalArchives of Biochemistry and Biophysics
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Inflammasomes
Gout
Interleukin-1
Uric Acid
Chemical activation
Pharmaceutical Preparations
Therapeutics
Crystals
Xanthine Oxidase
Drug Design
Phagocytes
Anti-Inflammatory Agents
Cytokines
Inflammation
Processing

Keywords

  • Autoinflammatory disease
  • Gout
  • Inflammasome
  • Interleukin 1
  • NLRP3

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology

Cite this

The NLRP3 inflammasome - interleukin 1 pathway as a therapeutic target in gout. / Szekanecz, Z.; Szamosi, Szilvia; Kovács, Gergő E.; Kocsis, Elek; Benkő, Sz.

In: Archives of Biochemistry and Biophysics, 01.01.2019.

Research output: Contribution to journalReview article

@article{09c067bb6b234f8dad39ea69adcdac99,
title = "The NLRP3 inflammasome - interleukin 1 pathway as a therapeutic target in gout",
abstract = "The NLRP3 inflammasome is implicated in the processing of the pro-inflammatory cytokine interleukin 1β. Inflammatory disorders associated with the activation of the NLRP3 inflammasome - IL-1 axis are termed autoinflammatory diseases. Gout is an autoinflammatory disease, which is triggered by the deposition of monosodium urate crystals of precipitated uric acid. It is characterized by recurrent attacks of inflammation due to the activation of phagocytic cells that try to clear the crystals. NLRP3 inflammasome-mediated IL-1β production plays a key role in the manifestation of the disease. Currently, the best approach to treat gout is to reduce uric acid concentration by targeting xanthine oxidase or uric acid transporters, or to use non-steroidal anti-inflammatory drugs. Nevertheless, most of these treatments are not effective enough and may results in side effects. During the past decades, our knowledge has greatly improved about the molecular mechanisms of NLRP3 activation. This knowledge enables and urges scientists to discover or design drugs that target pathways of NLRP3 inflammasome activation, or more preferentially, NLRP3 inflammasome itself. In this review, we discuss the already available drugs and products, that target the diverse pathways of the NLRP3 - IL-1β axis, and the future therapeutic perspectives.",
keywords = "Autoinflammatory disease, Gout, Inflammasome, Interleukin 1, NLRP3",
author = "Z. Szekanecz and Szilvia Szamosi and Kov{\'a}cs, {Gergő E.} and Elek Kocsis and Sz. Benkő",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.abb.2019.01.031",
language = "English",
journal = "Archives of Biochemistry and Biophysics",
issn = "0003-9861",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - The NLRP3 inflammasome - interleukin 1 pathway as a therapeutic target in gout

AU - Szekanecz, Z.

AU - Szamosi, Szilvia

AU - Kovács, Gergő E.

AU - Kocsis, Elek

AU - Benkő, Sz.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The NLRP3 inflammasome is implicated in the processing of the pro-inflammatory cytokine interleukin 1β. Inflammatory disorders associated with the activation of the NLRP3 inflammasome - IL-1 axis are termed autoinflammatory diseases. Gout is an autoinflammatory disease, which is triggered by the deposition of monosodium urate crystals of precipitated uric acid. It is characterized by recurrent attacks of inflammation due to the activation of phagocytic cells that try to clear the crystals. NLRP3 inflammasome-mediated IL-1β production plays a key role in the manifestation of the disease. Currently, the best approach to treat gout is to reduce uric acid concentration by targeting xanthine oxidase or uric acid transporters, or to use non-steroidal anti-inflammatory drugs. Nevertheless, most of these treatments are not effective enough and may results in side effects. During the past decades, our knowledge has greatly improved about the molecular mechanisms of NLRP3 activation. This knowledge enables and urges scientists to discover or design drugs that target pathways of NLRP3 inflammasome activation, or more preferentially, NLRP3 inflammasome itself. In this review, we discuss the already available drugs and products, that target the diverse pathways of the NLRP3 - IL-1β axis, and the future therapeutic perspectives.

AB - The NLRP3 inflammasome is implicated in the processing of the pro-inflammatory cytokine interleukin 1β. Inflammatory disorders associated with the activation of the NLRP3 inflammasome - IL-1 axis are termed autoinflammatory diseases. Gout is an autoinflammatory disease, which is triggered by the deposition of monosodium urate crystals of precipitated uric acid. It is characterized by recurrent attacks of inflammation due to the activation of phagocytic cells that try to clear the crystals. NLRP3 inflammasome-mediated IL-1β production plays a key role in the manifestation of the disease. Currently, the best approach to treat gout is to reduce uric acid concentration by targeting xanthine oxidase or uric acid transporters, or to use non-steroidal anti-inflammatory drugs. Nevertheless, most of these treatments are not effective enough and may results in side effects. During the past decades, our knowledge has greatly improved about the molecular mechanisms of NLRP3 activation. This knowledge enables and urges scientists to discover or design drugs that target pathways of NLRP3 inflammasome activation, or more preferentially, NLRP3 inflammasome itself. In this review, we discuss the already available drugs and products, that target the diverse pathways of the NLRP3 - IL-1β axis, and the future therapeutic perspectives.

KW - Autoinflammatory disease

KW - Gout

KW - Inflammasome

KW - Interleukin 1

KW - NLRP3

UR - http://www.scopus.com/inward/record.url?scp=85060845864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060845864&partnerID=8YFLogxK

U2 - 10.1016/j.abb.2019.01.031

DO - 10.1016/j.abb.2019.01.031

M3 - Review article

C2 - 30710503

AN - SCOPUS:85060845864

JO - Archives of Biochemistry and Biophysics

JF - Archives of Biochemistry and Biophysics

SN - 0003-9861

ER -